

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## PER3 RABBIT PAB

货号: S219095 产品全名: PER3 兔多抗 基因符号 GIG13; FASPS3 UNIPROT ID: P56645 (Gene Accession - BC026102)

背景: This gene is a member of the Period family of genes and is expressed in a circadian pattern in the suprachiasmatic nucleus, the primary circadian pacemaker in the mammalian brain. Genes in this family encode components of the circadian rhythms of locomotor activity, metabolism, and behavior. This gene is upregulated by CLOCK/ARNTL heterodimers but then represses this upregulation in a feedback loop using PER/CRY heterodimers to interact with CLOCK/ARNTL. Polymorphisms in this gene have been linked to sleep disorders. Multiple transcript variants encoding different isoforms have been found for this gene.

抗原: Fusion protein of human PER3

经过测试的应用:ELISA, IHC

推荐稀释比:IHC: 50-300; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling, Cardiovascular


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human esophagus cancer tissue using 219095(PER3 Antibody) at a dilution of 1/55(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with the fusion protein and then with 219095(Anti-PER3 Antibody) at dilution 1/55.



The image on the left is immunohistochemistry of paraffinembedded Human cervical cancer tissue using 219095(Anti-PER3 Antibody) at a dilution of 1/55.



In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with fusion protein and then with D225821(Anti-PER3 Antibody) at dilution 1/55.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010